Cancer remains one of the most complex and challenging diseases in modern medicine, making it a primary focus of global scientific research. Although significant progress has been achieved in understanding the genetic regulation and molecular mechanisms underlying cancer, the development of highly effective therapeutic strategies continues to be a critical challenge.

In recent years, nanotechnology has opened entirely new avenues for cancer diagnosis and treatment. Leveraging advantages such as precise tumor targeting, enhanced drug accumulation, and controllable drug release, nanomedicine has the potential to reduce treatment-related toxicity while improving patient outcomes, potentially transforming traditional cancer therapy paradigms.

Compared with conventional drugs, nanocarrier delivery systems can:

• Increase drug accumulation within tumor tissues
• Prolong systemic circulation time
• Reduce overall toxicity
• Improve the bioavailability of poorly soluble drugs
• Enable combination therapy and intelligent drug release

From early laboratory concepts to multiple approved nanomedicines now entering the market, nanotechnology is undergoing a critical transition from “scientific innovation” to “clinical translation.”

---

I. Successes and Misconceptions at the Laboratory Stage

At the laboratory level, nanomedicine has demonstrated several notable advantages:

Passive Targeting (EPR Effect)

The enhanced permeability and retention (EPR) effect of tumor vasculature allows nanoparticles to accumulate preferentially in tumors due to abnormal blood vessel permeability and impaired lymphatic drainage.

Active Targeting

By conjugating antibodies, peptides, or other ligands, nanoparticles can specifically recognize tumor-associated surface receptors.

Overcoming Multidrug Resistance

Nanocarriers may bypass drug efflux pumps such as P-gp, increasing intracellular drug concentration.

However, a major issue lies in the widespread reliance on subcutaneous xenograft mouse models (such as C57BL/6 tumor-bearing mice). These models often exhibit exaggerated angiogenesis and artificially amplified EPR effects.

In contrast, human tumors, orthotopic models, and patient-derived xenograft (PDX) models show highly heterogeneous EPR characteristics. Tumor accumulation levels reaching 30% injected dose (ID%) in laboratory studies often fail to exceed 5% in clinical settings.

---

II. Three Major Gaps in Clinical Translation

1. Heterogeneity of Physiological Barriers

Human tumors possess far more complex vascular density, interstitial pressure, and fibrosis than idealized laboratory models.

Large nanoparticles (>100 nm) struggle to penetrate dense stromal matrices, while smaller particles are rapidly cleared from circulation.

Moreover, tumor microenvironment characteristics — including pH, enzymatic profiles, and immune cell infiltration — vary significantly among patients and even between lesions within the same patient, causing many “universal” nanomedicines to fail clinically.

2. Redefinition of Pharmacokinetics and Safety

Nanomedicine fundamentally alters the biodistribution profile of the original drug.

Uptake by the reticuloendothelial system (RES), particularly in the liver and spleen, may introduce unexpected hepatotoxicity or immunogenicity.

For example, although polyethylene glycol (PEG)-modified nanoparticles can extend circulation time, they may also induce anti-PEG antibodies, leading to accelerated blood clearance (ABC phenomenon) and reduced therapeutic efficacy after repeated dosing.

3. Bottlenecks in Scale-Up and Quality Control

Significant discrepancies may arise between milligram-scale laboratory formulations and kilogram-scale industrial production, including differences in:

• Particle size distribution
• Drug loading efficiency
• Release kinetics

Stability issues of liposomes and polymeric nanoparticles — such as aggregation during storage or infusion — as well as sterilization challenges due to poor heat tolerance, are also common obstacles during regulatory approval.

---

III. Bridging the Gap — Strategies in Translational Medicine

Traditional Approach	Translation-Oriented Strategy
Subcutaneous xenograft models	Patient-derived xenografts (PDX), organoids, microfluidic chips
Maximizing tumor accumulation	Optimizing PK/PD relationships and therapeutic windows
Fixed formulation design	Adaptive systems (pH-responsive, enzyme-responsive)
Single-drug delivery	Immunotherapy combinations, chemo/gene co-delivery
Empirical dosing	Biomarker-driven patient stratification (e.g., SPARC expression, vascular permeability)

Representative Cases

Onivyde (Liposomal Irinotecan)

Developed for pancreatic cancer patients resistant to gemcitabine, Onivyde utilizes the EPR effect and prolonged circulation properties.

In Phase III clinical trials, it demonstrated improved overall survival (6.1 vs. 4.2 months). However, therapeutic benefit remained limited to specific biomarker-defined patient subgroups.

BIND-014

A PSMA-targeted nanoparticle developed for prostate cancer showed promising early-stage results but was ultimately discontinued due to insufficient clinical efficacy.

This outcome highlighted that physiological barriers in humans are far more complex than anticipated from mouse studies.

---

IV. The Rise of Nanomedicine in China and Global Competition

In recent years, China’s nanomedicine industry has rapidly entered the global innovation landscape.

From basic research and clinical translation to industrial deployment, China is gradually building an integrated innovation ecosystem that connects research, clinical practice, and pharmaceutical manufacturing.

Driven by supportive policies, increased capital investment, and the upgrading of the innovative pharmaceutical industry, Chinese companies and research institutions are accelerating development in areas such as:

• Lipid nanoparticle (LNP) platforms
• RNA delivery systems
• Tumor-targeted nanocarriers
• Stimuli-responsive nanomaterials
• Nano-immunotherapy platforms

Particularly with the rapid advancement of mRNA technologies and nucleic acid therapeutics, the importance of nanodelivery systems has become even more prominent.

Lipid nanoparticles have emerged as a core enabling platform for nucleic acid drugs while also helping Chinese biotech companies participate more actively in global biopharmaceutical competition.

Meanwhile, Chinese research institutions have achieved notable progress in multiple areas, including:

• Tumor microenvironment-responsive nanoplatforms
• Multifunctional theranostic systems
• Visualization and tracking technologies for nanomedicine
• Ultra-small nanoparticle research
• Development of biodegradable nanocarriers

These achievements continue to narrow the gap between China and internationally leading research institutions.

At the industrial level, Chinese innovative pharmaceutical companies are also transitioning from “generic following” toward “original innovation.”

Increasingly, companies are building proprietary nanomedicine platforms and advancing related products into international clinical development.

Some Chinese enterprises have already initiated collaborations with global pharmaceutical companies, biotechnology firms, and academic institutions to co-develop next-generation nanotherapeutics.

---

Conclusion

From nanoparticle engineering in the laboratory to real-world treatment applications in cancer patients, nanomedicine continues to shorten the distance between scientific discovery and clinical practice.

It represents not only an advancement in drug delivery technology, but also a broader transformation in oncology — from broad-spectrum cytotoxicity toward precision-controlled therapy.

As the era of precision medicine continues to evolve, nanotechnology is becoming an essential bridge connecting fundamental research, innovative drug development, and clinical application.

Within this global wave of innovation, an increasing number of internationally oriented medical service platforms are also actively facilitating access to innovative therapies and cross-border healthcare resources.

DengYueMed continues to monitor developments in nanomedicine, targeted therapy, cell therapy, and cutting-edge oncology technologies, while striving to promote international collaboration and improve accessibility to advanced medical innovations.

As cancer treatment continues to move toward greater precision and personalization, the gap between “laboratory innovation” and “clinical benefit” will continue to narrow through technological progress and industrial collaboration.